Dosing & Uses
Dosage Forms & Strengths
ophthalmic solution
- 0.004% (0.04 mg/mL)
Open-Angle Glaucoma
Indicated for reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Instill 1 gtt in affected eye qDay in the evening
Dosing considerations
Should not be administered more than once daily; more frequent administration of prostaglandin analogs shown to decrease the IOP lowering effect
Reduction of IOP starts approximately 2 hr after first administration with maximum effect reached after 12 hours
Drug may be used concomitantly with other topical ophthalmic drug products to lower IOP; if more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart
Safety and efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (4)
- bimatoprost
travoprost ophthalmic, bimatoprost. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
- latanoprost
latanoprost, travoprost ophthalmic. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
- latanoprostene bunod ophthalmic
travoprost ophthalmic, latanoprostene bunod ophthalmic. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
- tafluprost
travoprost ophthalmic, tafluprost. unspecified interaction mechanism. Avoid or Use Alternate Drug. Combined use of 2 or more ophthalmic prostaglandins may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
Monitor Closely (31)
- aspirin
travoprost ophthalmic, aspirin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- aspirin rectal
travoprost ophthalmic, aspirin rectal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- bromfenac ophthalmic
travoprost ophthalmic, bromfenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- celecoxib
travoprost ophthalmic, celecoxib. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- choline magnesium trisalicylate
travoprost ophthalmic, choline magnesium trisalicylate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- diclofenac
travoprost ophthalmic, diclofenac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- diclofenac ophthalmic
travoprost ophthalmic, diclofenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- diflunisal
travoprost ophthalmic, diflunisal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- etodolac
travoprost ophthalmic, etodolac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- fenoprofen
travoprost ophthalmic, fenoprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- flurbiprofen
travoprost ophthalmic, flurbiprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- flurbiprofen ophthalmic
travoprost ophthalmic, flurbiprofen ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ibuprofen
travoprost ophthalmic, ibuprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ibuprofen IV
travoprost ophthalmic, ibuprofen IV. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ibuprofen/famotidine
travoprost ophthalmic, ibuprofen/famotidine. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- indomethacin
travoprost ophthalmic, indomethacin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ketoprofen
travoprost ophthalmic, ketoprofen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ketorolac
travoprost ophthalmic, ketorolac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ketorolac intranasal
travoprost ophthalmic, ketorolac intranasal. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- ketorolac ophthalmic
travoprost ophthalmic, ketorolac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- meclofenamate
travoprost ophthalmic, meclofenamate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- mefenamic acid
travoprost ophthalmic, mefenamic acid. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- meloxicam
travoprost ophthalmic, meloxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- nabumetone
travoprost ophthalmic, nabumetone. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- naproxen
travoprost ophthalmic, naproxen. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- nepafenac ophthalmic
travoprost ophthalmic, nepafenac ophthalmic. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- oxaprozin
travoprost ophthalmic, oxaprozin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- piroxicam
travoprost ophthalmic, piroxicam. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- salsalate
travoprost ophthalmic, salsalate. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- sulindac
travoprost ophthalmic, sulindac. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
- tolmetin
travoprost ophthalmic, tolmetin. unspecified interaction mechanism. Use Caution/Monitor. There are conflicting reports from studies of either increased or decreased IOP when ophthalmic prostaglandins are coadministered with NSAIDs (either systemic or ophthalmic).
Minor (0)
Adverse Effects
>10%
Increased pigmentation of iris & periorbital tissue & increased pigmentation, thickening, elongation & growth of eyelashes (59%)
Ocular hyperemia (35-50%)
1-10%
Decreased visual acuity (5-10%)
Ocular discomfort (5-10%)
Foreign body sensation (5-10%)
Pain (5-10%)
Pruritus (5-10%)
Abnormal vision (1-4%)
Blepharitis (1-4%)
Blurred vision (1-4%)
Cataract (1-4%)
Conjunctivitis (1-4%)
Dry eye (1-4%)
Iris discoloration (1-4%)
Keratitis (1-4%)
Lid margin crusting (1-4%)
Photophobia (1-4%)
Subconjunctival hemorrhage (1-4%)
Tearing (1-4%)
Postmarketing Reports
Prostaglandin analogs reported to cause periorbital and lid changes including deepening of the eyelid sulcus
Warnings
Contraindications
None
Cautions
Treatment may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, and number of lashes; eyelash changes are usually reversible upon discontinuation of treatment
Treatment should be used with caution in patients with active intraocular inflammation (eg, uveitis) because inflammation may be exacerbated
Macular edema, including cystoid macular edema, reported during treatment with travoprost ophthalmic solution; this drug should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
This drug has not been evaluated for treatment of angle-closure, inflammatory or neovascular glaucoma
There have been reports of bacterial keratitis associated with use of multiple-dose containers of topical ophthalmic products; these containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface
Contact lenses should be removed prior to instillation of the drug and may be reinserted 15 minutes following its administration
Pigmentation
- Therapy reported to cause changes to pigmented tissues; most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes
- Pigmentation expected to increase as long as therapy administered; the pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes
- After discontinuation of therapy, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes reported to be reversible in some patients; patients who receive treatment should be informed of possibility of increased pigmentation
- The long-term effects of increased pigmentation are not known; iris color change may not be noticeable for several months to years; typically, the brown pigmentation around pupil spreads concentrically towards periphery of the iris and the entire iris or parts of the iris become more brownish
- Neither nevi nor freckles of the iris appear to be affected by treatment; while treatment can be continued in patients who develop noticeably increased iris pigmentation, patients should be examined regularly
Pregnancy & Lactation
Pregnancy
There are no adequate and well-controlled studies in pregnant women to inform a drug-associated risk; advise pregnant women of a potential risk to a fetus
Animal data
- Animal reproduction studies, subcutaneous (SC) administration to pregnant mice and rats throughout period of organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses
- Because animal reproductive studies are not always predictive of human response, administer during pregnancy only if potential benefit justifies potential risk to fetus
Lactation
There are no data on effects on breastfed child or milk production; it is not known if drug is present in human milk following ophthalmic administration
A study in lactating rats demonstrated that radio-labeled travoprost and/or its metabolites were excreted in milk following subcutaneous administration
Developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breast-fed child
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Absorption: through the cornea
Peak Plasma Time: within 30 min
Metabolism: hydrolyzed by esterases in the cornea
Excretion: urinary; complete systemic elimination within 1 hr
Mechanism of Action
Prostaglandin F2-alpha analog; incr outflow of aqueous humor
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| travoprost ophthalmic (eye) - | 0.004 % drops |  | |
| travoprost ophthalmic (eye) - | 0.004 % drops |  | |
| travoprost ophthalmic (eye) - | 0.004 % drops |  | |
| travoprost ophthalmic (eye) - | 0.004 % drops |  | |
| Travatan Z ophthalmic (eye) - | 0.004 % drops |  | |
| Travatan Z ophthalmic (eye) - | 0.004 % drops |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
travoprost ophthalmic (eye)
TRAVOPROST SOLUTION - OPHTHALMIC
(TRA-voh-prost)
COMMON BRAND NAME(S): Travatan
USES: Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.
HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start using travoprost and each time you get a refill. If you have any questions, ask your doctor or pharmacist.Apply this medication in the affected eye(s)as directed by your doctor, usually once a day in the evening. Do not use travoprost more often because it will not work as well.To apply eye drops, wash your hands first. To avoid contamination, do not touch the dropper tip or let it touch your eye or any other surface.Remove contact lenses before using this medication if your brand contains the preservative benzalkonium chloride. This preservative can be absorbed by contact lenses. Wait at least 15 minutes after using this medication before putting your lenses back in.Tilt your head back, look upward and pull down the lower eyelid to make a pouch. Hold the dropper directly over your eye and place one drop into the pouch. Look downward and gently close your eyes for 1 to 2 minutes. Place one finger at the corner of your eye (near the nose) and apply gentle pressure. This will prevent the medication from draining out. Try not to blink and do not rub your eye. Repeat these steps for your other eye if so directed.Do not rinse the dropper. Replace the dropper cap after each use.If you are using another kind of eye medication (such as drops or ointments), wait at least 5 minutes before applying other medications. Use eye drops before eye ointments to allow the eye drops to enter the eye.Use this medication regularly in order to get the most benefit from it. Remember to use it at the same time each day. Keep using travoprost even if you feel well. Most people with glaucoma or high pressure in the eye do not have symptoms.
SIDE EFFECTS: Blurred vision, eye redness/discomfort/itching, feeling as if something is in your eye, dry eyes, tearing, eyelid crusting, increase in eyelash number/length/thickness, darkening of the eyelashes and eyelids, eyelid changes, or increased sensitivity to light may occur. If any of these effects last or get worse, notify your doctor or pharmacist promptly.This medication may slowly (over months to years) cause brown discoloration of the colored portion of the eye (iris). If you are using travoprost in only one eye, only that iris may change color. This color change may be permanent, but the long-term effects are uncertain. Notify your doctor if this occurs and schedule regular eye exams to monitor it.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: vision changes, eye pain, swelling/redness of the eyelids.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before using travoprost, tell your doctor or pharmacist if you are allergic to it; or to similar drugs (such as bimatoprost, latanoprost); or if you have any other allergies. This product may contain inactive ingredients (such as preservatives like benzalkonium chloride found in some brands), which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: other eye problems (such as macular edema, iritis, uveitis, lens extraction/aphakia).If you develop an eye infection or injury, or have eye surgery, check with your doctor about the continued use of your current bottle of travoprost. You may be advised to start using a new bottle.After you apply this drug, your vision may become temporarily blurred. Do not drive, use machinery, or do any activity that requires clear vision until you can do it safely.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this medication passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug are: eyelash treatment (such as topically applied bimatoprost).
OVERDOSE: This medicine may be harmful if swallowed. If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Do not share this medication with others.Lab and/or medical tests (such as eye exams) should be done while you are using this medication. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store in the refrigerator or at room temperature. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised May 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
